All In Biotech

Drug Trial Radar · NCT07036510

Safety and Efficacy of TimoD Sustained-Release Implant in Participants With Glaucoma or Ocular Hypertension Undergoing Cataract Surgery

Early Feasibility Study to Evaluate the Safety and Efficacy of a New Timolol Sustained-Release Intraocular Implant (TimoD) in Participants With Open-Angle Glaucoma (OAG) or Ocular Hypertension (OHT) Undergoing Cataract Surgery

Last checked: Nov 20, 2026Latest source record: Jul 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

42

Planned (sponsor's estimate)

Start

Jun 12, 2025

Primary completion

Jan 2027

Study completion Jan 2027

Sponsor

Lead sponsor
EyeD PharmaIndustry
Sponsor type
Industry
First posted
Jun 25, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Other
FDA-regulated drug
No
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to test a new method to deliver an approved medicine called Timolol in the eye of participants with glaucoma or ocular hypertension and requiring cataract surgery. The study is conducted in two stages. The first stage (Stage 1/Phase 1) is intended to study the safety of 3 different doses of the study medication (called TimoD implant). The second stage (Stage 2/Phase 2) of the study is intended to study in greater detail the efficacy and safety of the 3 doses of the TimoD implant in comparison to a standard approved medication, timolol eye drops for 3 years.

Conditions

  • Glaucoma
  • Ocular Hypertension

Interventions

  • TimoD implantDrug

    Consists of 1 TimoD implant administration in the study eye.

  • Injector systemDevice

    This is a CE-marked injector intended for intraocular lens (IOL) delivery. In this study, the injector is used as an"intraocular implant injection system" outside of its scope of intended use.

  • Timolol eye drops 0.5%Drug

    Timolol eye drops will be self-admnistered twice daily in the study eye approximately 12 hours apart throughout the study

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Stage 1: Number (%) of participants experiencing adverse eventsTime frame: From Screening (up to Day -41) to end of stage 1 (Month 13)
  2. Stage 1: Number (%) of participants experiencing adverse events of special interest (AESI)Time frame: From Screening (up to Day -41) to end of stage 1 (Month 13)
  3. Stage 2: Proportion of responders defined as an IOP decrease of 20% or more between baseline and Month 3 (8 AM IOP)Time frame: Month 3
  4. Stage 2: Proportion of time-matched responders defined as an IOP decrease of 20% or more between baseline and Month 3 (8 AM and 10 AM)Time frame: Month 3

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Panama Eye Center

    Panama City, Panama · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.